- Juva Life (JUVA) has announced the launch of the Journal App for cannabis users and patients
- The app tracks consumption and provides insight into how cannabis products affect health and wellness
- The Journal App provides a personal tracking solution and provides Juva with valuable research information
- From cultivation to consumer, Juva Life takes a knowledge-driven approach to advance the therapeutic effects of cannabis
- Juva Life (JUVA) opened trading at C$0.20 per share
Juva Life (JUVA) has announced the launch of the Journal App.
The app is designed to help cannabis users and patients track their consumption and gain insight into how cannabis products affect their health and wellness.
“We’re proud to be one of the first and only companies to offer consumers a daily tracking solution that provides them a closer look at how their cannabis use affects their personal health and wellness,” said Doug Chloupek, CEO and Founder of Juva.
“One of Juva’s primary goals is to expand our industry’s knowledge of the medicinal effects of cannabis from a scientific perspective. The Journal App provides a personal tracking solution for our customers and it gives Juva information that compliments the data we collect via our research registry.”
Through the Journal App, cannabis consumers and anyone who uses hemp-based cannabidiol (CBD) products can track their symptoms, medication use and results. Consumers can track a variety of health ailments while documenting the products they consumed, the effect they had on their specific symptoms and any side effects that may occur.
“In all industries, data is king. Through both the Journal App and our WIRB-approved registry, we are curating one of the largest repositories of real-world data on the medical effects of cannabis use, including consumption behavior and perceived effectiveness. While we remain committed to the privacy of our users, the data we are collecting will be beneficial from a regulatory and scientific standpoint and adds significant value to Juva’s intellectual property portfolio,” added Chloupek.
“All user info associated with the Journal App and the WIRB-approved registry is protected by the strictest patient privacy laws in the world, so participants can rest assured their entries are 100 per cent confidential; any data imputed is anonymized for patient privacy.”
From cultivation to consumer, Juva Life takes a knowledge-driven approach to advance the therapeutic effects of cannabis.
Juva Life (JUVA) opened trading at C$0.20 per share.